Compositions and methods for cancer immunotherapy
US-9770467-B2 · Sep 26, 2017 · US
Compounds for the treatment of cancer
US11339188B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11339188-B2 |
| Application number | US-202016781352-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 4, 2020 |
| Priority date | Feb 17, 2017 |
| Publication date | May 24, 2022 |
| Grant date | May 24, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds useful for the treatment of cancer.
First claim
Opening claim text (preview).
We claim: 1. A compound or pharmaceutically acceptable salt thereof, selected from the group consisting of: 2. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound or pharmaceutically acceptable salt is Compound 2 or a pharmaceutically acceptable salt thereof. 3. The compound or pharmaceutically acceptable salt of claim 2 , wherein the compound is selected, and wherein the compound is Compound 2. 4. The compound or pharmaceutically acceptable salt of claim 2 , wherein the pharmaceutically acceptable salt is selected, and wherein the pharmaceutically acceptable salt is a diammonium salt of Compound 2. 5. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 2 and a pharmaceutically acceptable excipient. 6. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound or pharmaceutically acceptable salt is Compound 6 or a pharmaceutically acceptable salt thereof. 7. The compound or pharmaceutically acceptable salt of claim 6 , wherein the compound is selected, and wherein the compound is Compound 6. 8. The compound or pharmaceutically acceptable salt of claim 6 , wherein the pharmaceutically acceptable salt is selected, and wherein the pharmaceutically acceptable salt is a diammonium salt of Compound 6. 9. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 6 and a pharmaceutically acceptable excipient. 10. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound or pharmaceutically acceptable salt is Compound 26 or a pharmaceutically acceptable salt thereof. 11. The compound or pharmaceutically acceptable salt of claim 10 , wherein the compound is selected, and wherein the compound is Compound 26. 12. The compound or pharmaceutically acceptable salt of claim 10 , wherein the pharmaceutically acceptable salt is selected, and wherein the pharmaceutically acceptable salt is a diammonium salt of Compound 26. 13. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 10 and a pharmaceutically acceptable excipient. 14. The compound or pharmaceutically acceptable salt of claim 10 , wherein the pharmaceutically acceptable salt is selected, and wherein the pharmaceutically acceptable salt is a di-triethylamine salt of Compound 26. 15. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound or pharmaceutically acceptable salt is Compound 29 or a pharmaceutically acceptable salt thereof. 16. The compound or pharmaceutically acceptable salt of claim 15 , wherein the compound is selected, and wherein the compound is Compound 29. 17. The compound or pharmaceutically acceptable salt of claim 15 , wherein the pharmaceutically acceptable salt is selected, and wherein the pharmaceutically acceptable salt is a diammonium salt of Compound 29. 18. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 15 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Optical isomers · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
- C07H19/213Primary
containing cyclic phosphate · CPC title
Immunostimulants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11339188B2 cover?
- Provided herein are compounds useful for the treatment of cancer.
- Who is the assignee on this patent?
- Eisai R&D Man Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07H19/213. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).